Evaluate all GS, Ethics and Essays paper with model answers & detailed feedbackEvaluate Now

UPSC 2013 Mains GS3 Model Answer - What do you understand by fixed-dose drug combinations (FDCs)? Discuss their merits and demerits.

Feb, 2025

1 min read

Q14. What do you understand by fixed-dose drug combinations (FDCs)? Discuss their merits and demerits.

Model Answer:

Introduction

Fixed-dose drug combinations (FDCs) involve two or more active pharmaceutical ingredients combined in a single dosage form. Commonly used for conditions like diabetes, hypertension, HIV, and tuberculosis, FDCs aim to enhance patient compliance and therapeutic outcomes.

Body

Merits of FDCs

  • Improved Compliance: Simplifies treatment by reducing the number of pills, encouraging adherence.
  • Enhanced Efficacy: Combines drugs with synergistic effects, potentially increasing therapeutic effectiveness.
  • Convenience and Accessibility: Fewer medications to track, especially beneficial in chronic or multi-drug therapy.
  • Cost-effective: Reduces costs associated with treatment by bundling medications, often lowering the overall price.

Demerits of FDCs

  • Dosing Inflexibility: Fixed doses may not suit every patient, leading to potential underdosing or overdosing.
  • Adverse Drug Reactions (ADRs): Side effects from one component may limit or complicate the use of the entire combination.
  • Risk of Antibiotic Resistance: Misuse of FDC antibiotics can promote resistance due to improper dosing.
  • Quality Concerns: Requires stringent quality checks; without proper regulation, substandard FDCs may enter the market.

Conclusion

FDCs offer significant advantages for patient compliance and cost-effectiveness, particularly in chronic disease management. However, careful regulation and tailored dosing are essential to maximize benefits while minimizing risks of adverse effects and resistance.

Instant Mains Evaluation with SuperKalam

Share
SuperKalam is your personal mentor for UPSC preparation, guiding you at every step of the exam journey.
Follow us

ⓒ Snapstack Technologies Private Limited